DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2009/0292100 A1 Fiene Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2009/0292100 A1 Fiene Et Al US 20090292100A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2009/0292100 A1 Fiene et al. (43) Pub. Date: Nov. 26, 2009 (54) PROCESS FOR PREPARING (86). PCT No.: PCT/EP07/57646 PENTAMETHYLENE 1.5-DIISOCYANATE S371 (c)(1), (75) Inventors: Martin Fiene, Niederkirchen (DE): (2), (4) Date: Jan. 9, 2009 (DE);Eckhard Wolfgang Stroefer, Siegel, Mannheim (30) Foreign ApplicationO O Priority Data Limburgerhof (DE); Stephan Aug. 1, 2006 (EP) .................................. O61182.56.4 Freyer, Neustadt (DE); Oskar Zelder, Speyer (DE); Gerhard Publication Classification Schulz, Bad Duerkheim (DE) (51) Int. Cl. Correspondence Address: CSG 18/00 (2006.01) OBLON, SPIVAK, MCCLELLAND MAIER & CD7C 263/2 (2006.01) NEUSTADT, L.L.P. CI2P I3/00 (2006.01) 194O DUKE STREET CD7C 263/10 (2006.01) ALEXANDRIA, VA 22314 (US) (52) U.S. Cl. ........... 528/85; 560/348; 435/128; 560/347; 560/355 (73) Assignee: BASFSE, LUDWIGSHAFEN (DE) (57) ABSTRACT (21) Appl. No.: 12/373,088 The present invention relates to a process for preparing pen tamethylene 1,5-diisocyanate, to pentamethylene 1,5-diiso (22) PCT Filed: Jul. 25, 2007 cyanate prepared in this way and to the use thereof. US 2009/0292100 A1 Nov. 26, 2009 PROCESS FOR PREPARING ene diisocyanates, especially pentamethylene 1,4-diisocyan PENTAMETHYLENE 1.5-DIISOCYANATE ate. Depending on its preparation, this proportion may be up to several % by weight. 0014. The pentamethylene 1,5-diisocyanate prepared in 0001. The present invention relates to a process for pre accordance with the invention has, in contrast, a proportion of paring pentamethylene 1,5-diisocyanate, to pentamethylene the branched pentamethylene diisocyanate isomers of in each 1.5-diisocyanate prepared in this way and to the use thereof. case less than 100 ppm. 0002 The preparation of pentamethylene diisocyanate 0015 The present process therefore further provides a from 1.5-pentanediamine is known perse and can be effected mixture consisting of at least two different pentamethylene without phosgene (T. Lesiak, K. Seyda, Journal für Praktische diisocyanate isomers, of which the main constituent is pen Chemie (Leipzig), 1979,321 (1), 161-163) or by reaction with tamethylene 1,5-diisocyanate, and the isomer present in phosgene (e.g. DE 2625075). Smaller amounts is present in amounts of not more than 100 0003. DE 1900514 (corresponding to GB 1225450) ppm, with the proviso that the sum is 100% by weight. describes the two-stage preparation of pentamethylene 1.5- 0016. The present process further provides a mixture con diisocyanate from caprolactam by conversion to the hydrox sisting of pentamethylene 1,5-diisocyanate and pentamethyl amic acids and the Subsequent phosgenation thereof. ene 1,4-diisocyanate, where the proportion of pentamethyl 0004. The yield reported in this document for the conver ene 1,4-diisocyanate amounts to not more than 10 000 ppm, sion of caprolactam to pentamethylene 1,5-diisocyanate is preferably 7500 ppm, more preferably 5000 ppm, even more only approx. 32%. preferably 2500 ppm, in particular 1000 ppm, especially 500 0005 Caprolactam is prepared on the industrial scale ppm and even 100 ppm, and the proportion of pentamethylene either in several stages from benzene by ring hydrogenation 1,5-diisocyanate makes up the remainder to 100% by weight. to cyclohexane, oxidation to cyclohexanone and Beckmann 0017 Consequently, the pentamethylene 1,5-diisocyanate rearrangement with hydroxylamine, or from 1,4-butadiene by prepared in accordance with the invention has virtually exclu hydrocyanation and selective hydrogenation and Subsequent sively two primary isocyanate groups and therefore exhibits a cyclization to the caprolactam. In both cases, the basis is a more homogeneous reactivity in conversions of the isocyan hydrocarbon from petrochemistry. ate groups, for example in the preparation of polyurethanes. 0006. This is therefore a petrochemistry-based prepara Branched pentamethylene diisocyanate isomers, in contrast, tion over five stages in each case, proceeding from benzene or have one primary and one secondary isocyanate group, which from butadiene. are of different reactivity. 0007. The preparation of 1,5-pentanediamine is known by 0018. The pentamethylene 1,5-diisocyanate obtained by enzymatic decarboxylation of lysine with, for example, the process according to the invention generally has a color lysine decarboxylase (EP 1482055A1 or JP 2004-222569A) number of not more than 15 APHA to DIN ISO 6271. in a cell-free system or by thermal or catalytic decarboxyla 0019. The inventive step b) consists of a conversion of tion (G. Gautret de la Moriciere, G. Chatelus, Bull. Soc. lysine to 1.5-pentanediamine. Chim. France, 1969, 12, 4421-4425) or by hydrogenation of 0020 Lysine can be used in pure form or can actually be the corresponding nitriles (for example EP 161419 or WO formed in the course of the reaction (see below for step a)). In 2003/99768). addition, lysine can in the form of an aqueous solution, buffer 0008 1.5-Pentanediamine has to date not been available Solution or in the form of alysine-containing reaction mixture on the industrial scale. with alysine content of preferably from at least 5% by weight 0009 WO 2006/005603 describes a biochemical process up to the solubility limit in the particular reaction mixture at for preparing 1,4-butanediamine from ornithine with the aid the particular temperatures. In general, the content may be up of ornithine decarboxylase and the use thereof as a starting to 45% by weight, preferably up to 40, more preferably up to compound for polyamide preparation. 35 and most preferably up to 30% by weight. 0010. It was an object of the present invention to prepare 0021. The lysine (2,6-diaminohexanoic acid) used for the pentamethylene 1,5-diisocyanate which can be prepared process according to the invention originates from preferably from renewable raw materials. biological material and may be present in the form of the D 0011. This object is achieved by a process for preparing enantiomer, in the form of the Lenantiomer or in the form of pentamethylene 1,5-diisocyanate, in which any mixture of these enantiomers, for example in the form of b) lysine is converted to 1.5-pentanediamine and a racemate, preferably in the form of the Lenantiomer (S)- c) the 1.5-pentanediamine thus obtained is converted to pen 2,6-diaminohexanoic acid. tamethylene 1,5-diisocyanate. 0022. It can be used infree form or as an internal salt, in the 0012. The advantage of the process according to the inven form of its anion as a carboxylate, or mono- or diprotonated in tion is based on independence from mineral oil as the raw the form of its mono- or diammonium salt, for example as the material basis in the preparation of the pentamethylene 1.5- chloride. diisocyanate. In addition, the pentamethylene 1,5-diisocyan 0023. In addition, the lysine can be used in the form of its ate prepared in this way has less color than that prepared ester, for example as the methyl, ethyl, n-propyl, isopropyl. conventionally, since it is subjected to less thermal stress. n-butyl, sec-butyl or isobutyl ester. 0013. As a result of the inventive selection of the raw 0024 Step b) is preferably a decarboxylation. material basis of lysine or renewable raw materials, the pro 0025. In one possible decarboxylation, lysine, if appropri cess according to the invention affords at least virtually iso ate dissolved or Suspended in a solvent, is heated at a tem merically pure pentamethylene 1,5-diisocyanate, whereas the perature above 80°C., preferably above 100° C., more pref pentamethylene 1,5-diisocyanate prepared by the conven erably above 120° C., even more preferably above 150° C. tional route comprises a proportion of isomeric pentamethyl and in particular above 180° C. (thermal decarboxylation). US 2009/0292100 A1 Nov. 26, 2009 0026. The temperature may be up to 250°C., preferably up metal oxides, hydroxides, carbonates or hydrogencarbonates, to 23.0°C., more preferably up to 210°C. and most preferably preferably sodium hydroxide solution, potassium hydroxide up to 200° C. Solution, sodium hydrogencarbonate, Sodium carbonate, 0027. If appropriate, pressure can be applied in order to potassium hydrogencarbonate, calcium hydroxide, milk of keep any solvent present in the reaction mixture. lime or potassium carbonate (catalytic decarboxylation). 0028. Examples of solvents are aromatic and/or (cyclo) 0040 Especially when lysine is used in the form of an aliphatic hydrocarbons and mixtures thereof, halogenated ester, preferably of the methyl ester, performance of the reac hydrocarbons, esters, ethers and alcohols. tion as a dealkoxycarbonylation under so-called “Krapcho' 0029 Preference is given to aromatic hydrocarbons, (cy conditions is preferred, in which case a nucleophile, prefer clo)aliphatic hydrocarbons, alkyl alkanoates, alkoxylated ably an iodide or bromide, more preferably an iodide, is added alkyl alkanoates and mixtures thereof. to the reaction mixture which is heated under these reaction 0030 Particular preference is given to mono- or polyalky conditions. lated benzenes and naphthalenes, alkyl alkanoates and 0041. However, particular preference is given to perform alkoxylated alkyl alkanoates, and mixtures thereof. ing the decarboxylation with the aid of an enzyme. 0031 Preferred aromatic hydrocarbon mixtures are those 0042. The enzymes are preferably lyases (E.C. 4.--...-), which comprise predominantly aromatic C7- to C-hydro more preferably carbon-carbon lyases (E.C. 4.1.-...-) and most carbons and may comprise a boiling range of from 110 to preferably carboxy lyases (E.C. 4.1.1.-) 300° C.; particular preference is given to toluene, o-, m- or 0043. Examples Thereof are: p-Xylene, trimethylbenzene isomers, tetramethylbenzene iso EC 4.1.1.1 pyruvate decarboxylase mers, ethylbenzene, cumene, tetrahydronaphthalene and EC 4.1.1.2 oxalate decarboxylase mixtures comprising them. EC 4.1.1.3 oxaloacetate decarboxylase 0032 Examples thereof are the Solvesso(R) brands from EC 4.1.1.4 acetoacetate decarboxylase ExxonMobil Chemical, particularly Solvesso(R) 100 (CAS EC 4.1.1.5 acetolactate decarboxylase No.
Load more

Recommended publications
  • Proteomic Analysis of Mycelial Proteins from Magnaporthe Oryzae Under Nitrogen Starvation
    Proteomic analysis of mycelial proteins from Magnaporthe oryzae under nitrogen starvation X.-G. Zhou1,2, P. Yu 2, C. Dong2, C.-X. Yao2, Y.-M. Ding2, N. Tao2 and Z.-W. Zhao1 1State Key Laboratory for Conservation and Utilization of Bio-Resources in Yunnan, Yunnan University, Kunming, China 2Key Laboratory of Southwestern Crop Gene Resources and Germplasm Innovation, Ministry of Agriculture and Yunnan Provincial Key Laboratory of Agricultural Biotechnology, Biotechnology and Germplasm Resources Institute, Yunnan Academy of Agricultural Sciences, Kunming, China Corresponding author: Z.W. Zhao E-mail: [email protected] Genet. Mol. Res. 15 (2): gmr.15028637 Received March 23, 2016 Accepted April 11, 2016 Published May 13, 2016 DOI http://dx.doi.org/10.4238/gmr.15028637 ABSTRACT. Magnaporthe oryzae is an important model system in studies of plant pathogenic fungi, and nitrogen is a key nutrient source affecting microbial growth and development. In order to understand how nitrogen stress causes changes in mycelial proteins, we analyzed differentially expressed mycelial proteins from the M. oryzae virulent strain CH-63 using two-dimensional electrophoresis and mass spectrometry in complete medium or under nitrogen starvation conditions. A total of 975 ± 70 and 1169 ± 90 protein spots were detected in complete medium and under nitrogen starvation conditions, respectively. Forty-nine protein spots exhibited at least 2-fold up- regulation or down-regulation at the protein level according to PDQuest7.4. Moreover, 43 protein spots were successfully identified by matrix-assisted laser desorption/ionization-time-of-flight/time-of-flight mass spectrometry. Among these spots, 6 proteins were functionally unknown and 37 proteins were categorized into 5 groups according to Genetics and Molecular Research 15 (2): gmr.15028637 ©FUNPEC-RP www.funpecrp.com.br X.-G.
    [Show full text]
  • Aliphatic 1-Amino Acid Decarboxylase from Ferns (Filicopsida) Thomas Hartmann
    Aliphatic 1-Amino Acid Decarboxylase from Ferns (Filicopsida) Thomas Hartmann. Klaus Bax. and Renate Scholz Institut für Pharmazeutische Biologie der Technischen Universität Braunschweig, Mendels- sohnstr. 1, D-3300 Braunschweig. Bundesrepublik Deutschland Z. Naturforsch. 39c, 2 4 -3 0 (1984); received Septem ber 26, 1983 Ferns, Filicopsida, Polypodium vulgare. Aliphatic 1-Amino Acid Decarboxylase, Occurrence and Distribution A screening of 27 fern species (Filicopsida) out of 9 families revealed that 25 species were able to decarboxylate 1-leucine to 3-methylbutylamine (isoamylamine). The enzyme of Polvpodium vulgäre has partially been purified and characterisized. All attempts to solubilize it from acetone preparations failed; however, approx. 50% of total activity could be extracted from dry material in the presence of detergents at high concentration. The soluble enzyme was purified 132-fold. 1-Methionine was found the best substrate followed by norvaline, leucine, norleucine, isoleucine, homocysteine, valine. It has been confirmed that these substrates are decarboxylated by a single enzyme. The pH-optimum was at pH 5.0 (particulate preparation) and pH 4.5 (soluble enzyme). Decarboxylation is dependent on pyridoxal-5'-phosphate (PLP). A strictly substrate dependent coenzyme dissociation was observed which could largely be prevented by addition of 2 -oxo-acids, such as glyoxylate or pyruvate. Apodecarboxylase prepared by prolonged substrate incubation was found to be extremely labile at pH 4.5 but stable at pH 6.5. A comparison of the fern enzyme with bacterial valine decarboxylase (EC 4.1.1.14) and leucine decarboxylase of red algae revealed great similarities especially in substrate specificity. It is suggested to unify these activities as “aliphatic 1-amino acid decarboxylase”.
    [Show full text]
  • Oxdc Antibody Rabbit Polyclonal Antibody Catalog # ABV11223
    10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.622.0609 OxdC Antibody Rabbit Polyclonal Antibody Catalog # ABV11223 Specification OxdC Antibody - Product Information Application WB Primary Accession O34714 Reactivity Human Host Rabbit Clonality Polyclonal Isotype Rabbit IgG Calculated MW 43566 OxdC Antibody - Additional Information Gene ID 938620 Positive Control Western Blot: Recombinant protein Application & Usage Western blot: 1-4 Western blot of Oxalate decarboxylase µg/ml. antibody. Lane 1: rb- Oxalate decarboxylase - Other Names 10 ng. Lane 2: rb- Oxalate decarboxylase - 50 YvrK ng Target/Specificity OxdC OxdC Antibody - Background Antibody Form Oxalate decarboxylase (OxdC, EC4.1.1.2) is a Liquid manganese-containing enzyme, which decomposes oxalic acid and oxalate. With Appearance OxdC catalysis, oxalate is split into formate Colorless liquid and CO2. This enzyme belongs to the family of lyases, specifically the carboxy-lyases, which Formulation 100 µg (0.5 mg/ml) of antibody in PBS pH cleave carbon-carbon bonds. The systematic 7.2 containing 0.01 % BSA, 0.01 % name of this enzyme class is oxalate thimerosal, and 50 % glycerol. carboxy-lyase (formate-forming). This enzyme is also called oxalate carboxy-lyase. The Handling enzyme is composed of two cupin domains, The antibody solution should be gently each of which contains a Mn (II) ion. This mixed before use. enzyme participates in glyoxylate and dicarboxylate metabolism. This enzyme has Reconstitution & Storage been recognized for diagnostics in diverse -20 °C biotechnological applications such as the clinical assay of oxalate in blood and urine, Background Descriptions therapeutics, process industry, and agriculture to lower oxalate levels in foods and the environment.
    [Show full text]
  • Proteo-Metabolomic Investigation of Transgenic Rice Unravels Metabolic
    www.nature.com/scientificreports OPEN Proteo-metabolomic investigation of transgenic rice unravels metabolic alterations and Received: 27 November 2018 Accepted: 24 June 2019 accumulation of novel proteins Published: xx xx xxxx potentially involved in defence against Rhizoctonia solani Subhasis Karmakar1, Karabi Datta1, Kutubuddin Ali Molla2,3, Dipak Gayen4, Kaushik Das1, Sailendra Nath Sarkar1 & Swapan K. Datta1 The generation of sheath blight (ShB)-resistant transgenic rice plants through the expression of Arabidopsis NPR1 gene is a signifcant development for research in the feld of biotic stress. However, to our knowledge, regulation of the proteomic and metabolic networks in the ShB-resistant transgenic rice plants has not been studied. In the present investigation, the relative proteome and metabolome profles of the non–transformed wild-type and the AtNPR1-transgenic rice lines prior to and subsequent to the R. solani infection were investigated. Total proteins from wild type and transgenic plants were investigated using two-dimensional gel electrophoresis (2-DE) followed by mass spectrometry (MS). The metabolomics study indicated an increased abundance of various metabolites, which draws parallels with the proteomic analysis. Furthermore, the proteome data was cross-examined using network analysis which identifed modules that were rich in known as well as novel immunity-related prognostic proteins, particularly the mitogen-activated protein kinase 6, probable protein phosphatase 2C1, probable trehalose-phosphate phosphatase 2 and heat shock protein. A novel protein, 14–3– 3GF14f was observed to be upregulated in the leaves of the transgenic rice plants after ShB infection, and the possible mechanistic role of this protein in ShB resistance may be investigated further.
    [Show full text]
  • Kenneth M. Roberts
    Kenneth M. Roberts Assistant Professor of Chemistry Department of Chemistry and Physics University of South Carolina Aiken SBDG 322A 471 University Parkway Aiken, SC 29801 (803) 641-3561 [email protected] EDUCATION and EXPERIENCE Aug 2015 - present Assistant Professor University of South Carolina Courses: Introductory Chemistry (CHEM A101) Aiken General Chemistry (CHEM A111, A112) Organic Chemistry (CHEM A331L, A332L) Biochemistry (BIOL A541, CHEM A550) Research: Investigating the mechanisms of the metal-dependent enzymes 2,4’-dihydroxyacetophenone dioxygenase and gallate decarboxylase Fall 2012 - Spring 2014 Adjunct Professor Fall 2011 General Chemistry (CH 1401 and 1402) St. Mary’s University Organic Chemistry (CH 3411 and 3412) 80 contact hours: lecture 100 contact hours: laboratory Apr 2010 – Jul 2015 Post-Doctoral Associate, Department of Biochemistry University of Texas Health Focus: Investigation of the mechanism of the aromatic amino acid Science Center at San Antonio hydroxylases using rapid-reaction techniques. Advisor: Dr. Paul F. Fitzpatrick Dec 2009 - Mar 2010 Post-Doctoral Associate, Department of Chemistry Washington State University Focus: Investigation of the mechanism of benzylic hydroxylation and N-dealkylation in a key catalytic mutant of cytochrome P450. Advisor: Dr. Jeffrey P. Jones Dec 2009 Ph.D. Biochemistry Washington State University Thesis: Mechanistic evaluation of N-dealkylation by cytochrome P450 using N,N-dimethylaniline N-oxides and kinetic isotope effects Advisor: Dr. Jeffrey P. Jones Summer 2008 Lecturer/Teaching Assistant Washington State University Chemistry Related to Life Sciences (CHEM 102) 40 contact hours Mar 1996 B.S. Biochemistry University of Washington PUBLICATIONS *denotes undergraduate researchers Roberts, K. M., Connor, G. C.*, Cave, C. H.*, Rowe, G.
    [Show full text]
  • Supplementary Materials
    1 Supplementary Materials: Supplemental Figure 1. Gene expression profiles of kidneys in the Fcgr2b-/- and Fcgr2b-/-. Stinggt/gt mice. (A) A heat map of microarray data show the genes that significantly changed up to 2 fold compared between Fcgr2b-/- and Fcgr2b-/-. Stinggt/gt mice (N=4 mice per group; p<0.05). Data show in log2 (sample/wild-type). 2 Supplemental Figure 2. Sting signaling is essential for immuno-phenotypes of the Fcgr2b-/-lupus mice. (A-C) Flow cytometry analysis of splenocytes isolated from wild-type, Fcgr2b-/- and Fcgr2b-/-. Stinggt/gt mice at the age of 6-7 months (N= 13-14 per group). Data shown in the percentage of (A) CD4+ ICOS+ cells, (B) B220+ I-Ab+ cells and (C) CD138+ cells. Data show as mean ± SEM (*p < 0.05, **p<0.01 and ***p<0.001). 3 Supplemental Figure 3. Phenotypes of Sting activated dendritic cells. (A) Representative of western blot analysis from immunoprecipitation with Sting of Fcgr2b-/- mice (N= 4). The band was shown in STING protein of activated BMDC with DMXAA at 0, 3 and 6 hr. and phosphorylation of STING at Ser357. (B) Mass spectra of phosphorylation of STING at Ser357 of activated BMDC from Fcgr2b-/- mice after stimulated with DMXAA for 3 hour and followed by immunoprecipitation with STING. (C) Sting-activated BMDC were co-cultured with LYN inhibitor PP2 and analyzed by flow cytometry, which showed the mean fluorescence intensity (MFI) of IAb expressing DC (N = 3 mice per group). 4 Supplemental Table 1. Lists of up and down of regulated proteins Accession No.
    [Show full text]
  • Arginine Enzymatic Deprivation and Diet Restriction for Cancer Treatment
    Brazilian Journal of Pharmaceutical Sciences Review http://dx.doi.org/10.1590/s2175-97902017000300200 Arginine enzymatic deprivation and diet restriction for cancer treatment Wissam Zam* Al-Andalus University for Medical Sciences, Faculty of Pharmacy, Analytical and Food Chemistry, Tartous, Syrian Arab Republic Recent findings in amino acid metabolism and the differences between normal, healthy cells and neoplastic cells have revealed that targeting single amino acid metabolic enzymes in cancer therapy is a promising strategy for the development of novel therapeutic agents. Arginine is derived from dietary protein intake, body protein breakdown, or endogenous de novo arginine production and several studies have revealed disturbances in its synthesis and metabolism which could enhance or inhibit tumor cell growth. Consequently, there has been an increased interest in the arginine-depleting enzymes and dietary deprivation of arginine and its precursors as a potential antineoplastic therapy. This review outlines the most recent advances in targeting arginine metabolic pathways in cancer therapy and the different chemo- and radio-therapeutic approaches to be co-applied. Key words: Arginine-depleting enzyme/antineoplastic therapy. Dietary deprivation. INTRODUCTION variety of human cancer cells have been found to be auxotrophic for arginine, depletion of which results in Certain cancers may be auxotrophic for a particular cell death (Tytell, Neuman, 1960; Kraemer, 1964; Dillon amino acid, and amino acid deprivation is one method to et al., 2004). Arginine can be degraded by three enzymes: treat these tumors. The strategy of enzymatic degradation arginase, arginine decarboxylase and arginine deiminase of amino acids to deprive malignant cells of important (ADI). Both arginine decarboxylase and ADI are not nutrients is an established component of induction therapy expressed in mammalian cells (Morris, 2007; Miyazaki of several tumor cells.
    [Show full text]
  • Gut Bacterial Tyrosine Decarboxylases Restrict the Bioavailability Of
    bioRxiv preprint doi: https://doi.org/10.1101/356246; this version posted August 21, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Title: Gut bacterial tyrosine decarboxylases restrict the bioavailability of levodopa, the primary treatment in Parkinson’s disease Authors: Sebastiaan P. van Kessel1, Alexandra K. Frye1, Ahmed O. El-Gendy1,2, Maria Castejon1, Ali Keshavarzian3, Gertjan van Dijk4, Sahar El Aidy1*† Affiliations: 1 Department of Molecular Immunology and Microbiology, Groningen Biomolecular Sciences and Biotechnology Institute (GBB), University of Groningen, Groningen, The Netherlands. 2 Department of Microbiology and Immunology, Faculty of Pharmacy, Beni-Suef University, Beni-Suef, Egypt 3 Division of Digestive Disease and Nutrition, Section of Gastroenterology, Department of Internal Medicine, Rush University Medical Center, Chicago, Illinois. 4 Department of Behavioral Neuroscience, Groningen Institute for Evolutionary Life Sciences (GELIFES), University of Groningen, Groningen, The Netherlands. * Corresponding author. Email: [email protected] † Present address: Groningen Biomolecular Sciences and Biotechnology Institute (GBB), University of Groningen, Nijenborg 7, 9747 AG Groningen, The Netherlands. P:+31(0)503632201. 1 bioRxiv preprint doi: https://doi.org/10.1101/356246; this version posted August 21, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Summary Human gut bacteria play a critical role in the regulation of immune and metabolic systems, as well as in the function of the nervous system. The microbiota senses its environment and responds by releasing metabolites, some of which are key regulators of human health and disease.
    [Show full text]
  • Generate Metabolic Map Poster
    Authors: Pallavi Subhraveti Anamika Kothari Quang Ong Ron Caspi An online version of this diagram is available at BioCyc.org. Biosynthetic pathways are positioned in the left of the cytoplasm, degradative pathways on the right, and reactions not assigned to any pathway are in the far right of the cytoplasm. Transporters and membrane proteins are shown on the membrane. Ingrid Keseler Peter D Karp Periplasmic (where appropriate) and extracellular reactions and proteins may also be shown. Pathways are colored according to their cellular function. Csac1394711Cyc: Candidatus Saccharibacteria bacterium RAAC3_TM7_1 Cellular Overview Connections between pathways are omitted for legibility. Tim Holland TM7C00001G0420 TM7C00001G0109 TM7C00001G0953 TM7C00001G0666 TM7C00001G0203 TM7C00001G0886 TM7C00001G0113 TM7C00001G0247 TM7C00001G0735 TM7C00001G0001 TM7C00001G0509 TM7C00001G0264 TM7C00001G0176 TM7C00001G0342 TM7C00001G0055 TM7C00001G0120 TM7C00001G0642 TM7C00001G0837 TM7C00001G0101 TM7C00001G0559 TM7C00001G0810 TM7C00001G0656 TM7C00001G0180 TM7C00001G0742 TM7C00001G0128 TM7C00001G0831 TM7C00001G0517 TM7C00001G0238 TM7C00001G0079 TM7C00001G0111 TM7C00001G0961 TM7C00001G0743 TM7C00001G0893 TM7C00001G0630 TM7C00001G0360 TM7C00001G0616 TM7C00001G0162 TM7C00001G0006 TM7C00001G0365 TM7C00001G0596 TM7C00001G0141 TM7C00001G0689 TM7C00001G0273 TM7C00001G0126 TM7C00001G0717 TM7C00001G0110 TM7C00001G0278 TM7C00001G0734 TM7C00001G0444 TM7C00001G0019 TM7C00001G0381 TM7C00001G0874 TM7C00001G0318 TM7C00001G0451 TM7C00001G0306 TM7C00001G0928 TM7C00001G0622 TM7C00001G0150 TM7C00001G0439 TM7C00001G0233 TM7C00001G0462 TM7C00001G0421 TM7C00001G0220 TM7C00001G0276 TM7C00001G0054 TM7C00001G0419 TM7C00001G0252 TM7C00001G0592 TM7C00001G0628 TM7C00001G0200 TM7C00001G0709 TM7C00001G0025 TM7C00001G0846 TM7C00001G0163 TM7C00001G0142 TM7C00001G0895 TM7C00001G0930 Detoxification Carbohydrate Biosynthesis DNA combined with a 2'- di-trans,octa-cis a 2'- Amino Acid Degradation an L-methionyl- TM7C00001G0190 superpathway of pyrimidine deoxyribonucleotides de novo biosynthesis (E.
    [Show full text]
  • Polyamine Biosynthesis in Human Fetal Liver and Brain
    Pediat. Res. 8: 231-237 (1974) S-Adenosylmethionine decarboxylase polyamines developmental biochemistry putrescine fetus spermidine ornithine decarboxylase Polyamine Biosynthesis in Human Fetal Liver and Brain JOHN A. STURMAN'~~]AND GERALD E. GAULL Department of Pediatric Research, Institute for Basic liesearch in Mental Retardation, Staten Island, and Department of Pediatrics, Division of Medical Genetics and Clinical Genetics Center, Mount Sinai School of Medicine of the City University of New York, New York, New York, USA Extract S-Adenosylmethionine decarboxylase specific activity in fetal (9.0-25.0 cm crown- rump length) human liver was 20-fold greater than in mature human liver, both in the absence of putrescine (63.1 f 7.2 versus 3.5 =t 0.8 pmol C02/mgprotein/30 min) or in the presence of putrescine (1 16.9 + 8.2 uersus 6.2 =I= 1.0 pmol C02/mg protein/30 min). Extracts of fetal human brain did not have a significantly greater specific ac- tivity of S-adenosylmethionine decarboxylase than extracts of mature human brain when assayed in the absence of putrescine and had less when assayed in the presence of putrescine (84.7 =t 14.9 versus 175.5 f 30.6 pmol C02/mgprotein/30 min). Ornithine decarboxylase specific activity was greater in fetal liver than in mature liver (8.8 =t1.6 versus 1.1 f 0.3 pmol CO 2/mg protein/30 min) and 20-fold greater in fetal brain than in mature brain (7 1.2 =t 12.1 uersus 3.1 =I= 1.4 pmol CO z/mg protein/30 min).
    [Show full text]
  • Structure and Ligands Interactions of Citrus Tryptophan Decarboxylase by Molecular Modeling and Docking Simulations
    Communication Structure and Ligands Interactions of Citrus Tryptophan Decarboxylase by Molecular Modeling and Docking Simulations Angelo Facchiano 1,*, Domenico Pignone 2, Luigi Servillo 3, Domenico Castaldo 4 and Luigi De Masi 5,* 1 Consiglio Nazionale delle Ricerche (CNR), Istituto di Scienze dell’Alimentazione (ISA), 83100 Avellino, Italy; [email protected] 2 CNR, Istituto di Bioscienze e BioRisorse (IBBR), 70126 Bari, Italy; [email protected] 3 Dipartimento di Medicina di Precisione, Università degli Studi della Campania “Luigi Vanvitelli”, 80138 Napoli, Italy; [email protected] 4 Stazione Sperimentale per le Industrie delle Essenze e dei Derivati dagli Agrumi (SSEA), Azienda Speciale della Camera di Commercio di Reggio Calabria, 89125 Reggio Calabria, Italy; [email protected] 5 CNR, IBBR, 80055 Portici, Italy; [email protected] * Correspondence: [email protected] (A.F.); [email protected] (L.D.M.). Received: 29 December 2019; Accepted: 22 March 2019; Published: 26 March 2019 Abstract: In a previous work, we in silico annotated protein sequences of Citrus genus plants as putative tryptophan decarboxylase (pTDC). Here, we investigated the structural properties of Citrus pTDCs by using the TDC sequence of Catharanthus roseus as an experimentally annotated reference to carry out comparative modeling and substrate docking analyses. The functional annotation as TDC was verified by combining 3D molecular modeling and docking simulations, evidencing the peculiarities and the structural similarities with C. roseus TDC. Docking with L-tryptophan as a ligand showed specificity of pTDC for this substrate. These combined results confirm our previous in silico annotation of the examined protein sequences of Citrus as TDC and provide support for TDC activity in this plant genus.
    [Show full text]
  • (10) Patent No.: US 8119385 B2
    US008119385B2 (12) United States Patent (10) Patent No.: US 8,119,385 B2 Mathur et al. (45) Date of Patent: Feb. 21, 2012 (54) NUCLEICACIDS AND PROTEINS AND (52) U.S. Cl. ........................................ 435/212:530/350 METHODS FOR MAKING AND USING THEMI (58) Field of Classification Search ........................ None (75) Inventors: Eric J. Mathur, San Diego, CA (US); See application file for complete search history. Cathy Chang, San Diego, CA (US) (56) References Cited (73) Assignee: BP Corporation North America Inc., Houston, TX (US) OTHER PUBLICATIONS c Mount, Bioinformatics, Cold Spring Harbor Press, Cold Spring Har (*) Notice: Subject to any disclaimer, the term of this bor New York, 2001, pp. 382-393.* patent is extended or adjusted under 35 Spencer et al., “Whole-Genome Sequence Variation among Multiple U.S.C. 154(b) by 689 days. Isolates of Pseudomonas aeruginosa” J. Bacteriol. (2003) 185: 1316 1325. (21) Appl. No.: 11/817,403 Database Sequence GenBank Accession No. BZ569932 Dec. 17. 1-1. 2002. (22) PCT Fled: Mar. 3, 2006 Omiecinski et al., “Epoxide Hydrolase-Polymorphism and role in (86). PCT No.: PCT/US2OO6/OOT642 toxicology” Toxicol. Lett. (2000) 1.12: 365-370. S371 (c)(1), * cited by examiner (2), (4) Date: May 7, 2008 Primary Examiner — James Martinell (87) PCT Pub. No.: WO2006/096527 (74) Attorney, Agent, or Firm — Kalim S. Fuzail PCT Pub. Date: Sep. 14, 2006 (57) ABSTRACT (65) Prior Publication Data The invention provides polypeptides, including enzymes, structural proteins and binding proteins, polynucleotides US 201O/OO11456A1 Jan. 14, 2010 encoding these polypeptides, and methods of making and using these polynucleotides and polypeptides.
    [Show full text]